34 results
8-K
EX-1.1
ANNX
Annexon Inc
7 Jun 24
Annexon Announces Pricing of $125 Million Underwritten Public Offering
4:42pm
with the design and implementation of such trials.
(dd) Compliance with Health Care Laws. Except as would not, individually or in the aggregate, reasonably … Care Laws. For purposes of this Agreement, “Health Care Laws” means: (i) the Federal Food, Drug, and Cosmetic Act and the regulations promulgated
8-K
EX-99.2
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
infusion ü Faster recovery / independence 90% of GBS patients treated with off-label IVIg in US ü Potential for significant cost reductions for health … care system ‐ Daily infusions over 5 days Robust HEOR plan to demonstrate reduced cost of care ‐ Non-specific approach to treating GBS Focused
8-K
EX-1.1
6uky3j
21 Dec 23
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
4:09pm
D
oh5a5a8i
22 Jul 22
$130.48M in equity / options / securities to be acquired, sold $130.48M, 12 investors
10:07am
8-K
EX-10.1
gdd1 r9ltu
8 Jul 22
Annexon Announces $130 Million Private Placement Financing
5:19pm
DEF 14A
pud4bqfz6jh
22 Apr 21
Definitive proxy
4:06pm